STAT+: Flagship’s Laronde raises $440 million for a new class of medicines

Flagship Pioneering, the Cambridge, Mass., venture capital firm, brought biotech startup Laronde out of stealth mode in May, launching it with $50 million after four years of secrecy.

It was the first time Laronde disclosed its technology: a proprietary molecule its scientists call “endless RNA,” which the company hopes will allow humans to produce their own proteins for weeks or months to treat diseases. Now, three months after making its public debut, Laronde announced it has raised $440 million from investors.

Continue to STAT+ to read the full story…

Read Original Article: STAT+: Flagship’s Laronde raises $440 million for a new class of medicines »